Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Invested Capital (2021 - 2025)

Bioregenx has reported Invested Capital over the past 5 years, most recently at -$3.5 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 57.67% year-over-year to -$3.5 million; the TTM value through Dec 2025 reached -$3.5 million, down 57.67%, while the annual FY2025 figure was -$3.5 million, 57.67% down from the prior year.
  • Invested Capital for Q4 2025 was -$3.5 million at Bioregenx, down from -$2.6 million in the prior quarter.
  • Over five years, Invested Capital peaked at $16.0 million in Q1 2024 and troughed at -$3.5 million in Q4 2025.
  • A 5-year average of $1.2 million and a median of -$2.2 million in 2023 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: crashed 2110.9% in 2022 and later surged 824.46% in 2024.
  • Year by year, Invested Capital stood at $115766.0 in 2021, then crashed by 2110.9% to -$2.3 million in 2022, then soared by 33.6% to -$1.5 million in 2023, then plummeted by 45.0% to -$2.2 million in 2024, then crashed by 57.67% to -$3.5 million in 2025.
  • Business Quant data shows Invested Capital for BRGX at -$3.5 million in Q4 2025, -$2.6 million in Q3 2025, and -$2.7 million in Q2 2025.